Toggle navigation
TWunroll
TWunroll
faq
Contact US
Michael Kronenberg
SubBasepair_Res
Looking into the literature, it seems like specifically targeting CD47 with an active IgG might maximize the ADCC of the IgG relative to other targets. There are 2 reasons for
Read more
Interesting Merck valued VelosBio's ROR1-based antibody technology at 2.75 billion with only preclinical data available. VelosBio's VLS-101 is an antibody carrying a spindle poison payload, which is toxic to all
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our
Cookie Policy
to improve your experience.
I agree